How effective is fenelidone in lowering urinary protein? Analysis of treatment effects and patient feedback

Finerenone (Finerenone) is a new type of mineralocorticoid receptor antagonist (MRA). It has shown good clinical prospects in the therapeutic effect of lowering urinary protein, especially for patients with chronic kidney disease and diabetes. It has a significant therapeutic effect. Fennelidone reduces renal inflammation and fibrosis mainly by inhibiting mineralocorticoid receptors, thereby reducing urinary protein excretion. The following is an analysis of the effect of fenelidone on reducing urinary protein.

The proteinuria-lowering effect of fenelidone is mainly related to its selective antagonism of mineralocorticoid receptors. Mineral corticoid receptors play an important role in the kidneys, heart and other tissues. Excessive activation of this receptor can lead to water and salt retention, increased blood pressure, kidney damage and other problems. By inhibiting this excessive activation, fenelidone reduces the inflammatory response in the renal tubulointerstitium, thereby reducing kidney damage and reducing urinary protein excretion. Studies have shown that fenelidone can effectively reduce urine protein levels and slow down the progression of renal failure in patients with diabetic nephropathy.

Clinical research data shows that fenelidone has a significant effect in reducing urinary protein. For example, in the FIDELIO-DKD study, fenelinone significantly reduced urinary protein excretion in patients with diabetic nephropathy, and the incidence of renal failure events was significantly lower in the fenelidone group compared with the placebo group. This study shows that fenelinone can reduce the excretion of urinary protein and reduce the risk of related kidney damage by improving the metabolic function of the kidneys. Additionally, fenelidone has demonstrated potential protective effects against cardiovascular events, making it a pleiotropic treatment.

According to patient feedback, the use of fenelinone is generally good. Many patients said that after using the drug, urinary protein was significantly reduced and renal function was gradually stabilized. Compared with traditional mineral corticosteroid receptor antagonists, fenelinone has milder side effects, especially with a lower risk of hyperkalemia. Therefore, many patients can persist in using it for a long time without serious adverse reactions. However, some patients still reported mild side effects such as headache, nausea, or diarrhea, but it was generally well tolerated.

Reference materials:https://www.kerendia.com/